HRP980187B1 - Influenza vaccine - Google Patents

Influenza vaccine

Info

Publication number
HRP980187B1
HRP980187B1 HR980187A HRP980187A HRP980187B1 HR P980187 B1 HRP980187 B1 HR P980187B1 HR 980187 A HR980187 A HR 980187A HR P980187 A HRP980187 A HR P980187A HR P980187 B1 HRP980187 B1 HR P980187B1
Authority
HR
Croatia
Prior art keywords
influenza vaccine
influenza
vaccine
Prior art date
Application number
HR980187A
Other languages
English (en)
Inventor
Gustaaf J M Van Scharrenburg
Rudi Brands
Original Assignee
Duphar Int Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8228174&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP980187(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Duphar Int Res filed Critical Duphar Int Res
Publication of HRP980187A2 publication Critical patent/HRP980187A2/hr
Publication of HRP980187B1 publication Critical patent/HRP980187B1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16051Methods of production or purification of viral material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16211Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
HR980187A 1997-04-09 1998-04-06 Influenza vaccine HRP980187B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97201007 1997-04-09

Publications (2)

Publication Number Publication Date
HRP980187A2 HRP980187A2 (en) 1999-04-30
HRP980187B1 true HRP980187B1 (en) 2001-04-30

Family

ID=8228174

Family Applications (1)

Application Number Title Priority Date Filing Date
HR980187A HRP980187B1 (en) 1997-04-09 1998-04-06 Influenza vaccine

Country Status (32)

Country Link
US (1) US5948410A (xx)
EP (1) EP0870508B1 (xx)
JP (1) JP5258127B2 (xx)
KR (1) KR100593235B1 (xx)
CN (1) CN1138564C (xx)
AR (1) AR011216A1 (xx)
AT (1) ATE197406T1 (xx)
AU (1) AU728939B2 (xx)
BR (1) BR9801015A (xx)
CA (1) CA2234208C (xx)
CZ (1) CZ297492B6 (xx)
DE (2) DE870508T1 (xx)
DK (1) DK0870508T3 (xx)
DZ (1) DZ2462A1 (xx)
ES (1) ES2129386T3 (xx)
GR (2) GR990300017T1 (xx)
HK (1) HK1010833A1 (xx)
HR (1) HRP980187B1 (xx)
HU (1) HUP9800802A3 (xx)
ID (1) ID20399A (xx)
IL (1) IL123961A (xx)
NO (1) NO323349B1 (xx)
NZ (1) NZ330131A (xx)
PL (1) PL187982B1 (xx)
PT (1) PT870508E (xx)
RU (1) RU2197264C2 (xx)
SI (1) SI0870508T1 (xx)
SK (1) SK282614B6 (xx)
TR (1) TR199800613A1 (xx)
TW (1) TW570803B (xx)
UA (1) UA42089C2 (xx)
ZA (1) ZA982915B (xx)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2383105C (en) * 1999-09-24 2010-01-26 Smithkline Beecham Biologicals S.A. Intranasal influenza virus vaccine
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
CN100415769C (zh) * 2002-02-07 2008-09-03 中国科学院过程工程研究所 寡聚或多聚亚基蛋白质分离纯化的方法
BR0309659A (pt) 2002-04-30 2005-02-22 Oncolytics Biotech Inc Método para produzir vìrus de uma cultura de células, composição, e, método para produzir reovìrus infeccioso
US20060110406A1 (en) * 2003-02-25 2006-05-25 Medimmune Vaccines, Inc. Refrigerator-temperature stable influenza vaccine compositions
JP4617300B2 (ja) * 2003-02-25 2011-01-19 メディミューン,エルエルシー インフルエンザワクチン組成物を生成する方法
US7270990B2 (en) * 2003-06-20 2007-09-18 Microbix Biosystems, Inc. Virus production
US8506967B2 (en) 2003-07-11 2013-08-13 Novavax, Inc. Functional influenza virus like particles (VLPs)
US8080255B2 (en) 2003-07-11 2011-12-20 Novavax Inc. Functional influenza virus like particles (VLPs)
US8992939B2 (en) 2003-07-11 2015-03-31 Novavax, Inc. Highly efficient influenza matrix (M1) proteins
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
NZ548495A (en) 2004-02-23 2009-05-31 Crucell Holland Bv Virus purification methods
WO2005107797A1 (en) 2004-03-09 2005-11-17 Chiron Corporation Influenza virus vaccines
ES2386272T3 (es) 2004-09-09 2012-08-16 Novartis Vaccines And Diagnostics Gmbh Reducción de riesgos iatrogénicos potenciales asociados a las vacunas antigripales
US7901921B2 (en) 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
AU2005314563B2 (en) 2004-11-03 2011-06-30 Seqirus UK Limited Influenza vaccination
US7670837B2 (en) * 2004-12-23 2010-03-02 Medimmune, Llc Non-tumorigenic MDCK cell line for propagating viruses
KR20070116650A (ko) 2005-03-23 2007-12-10 글락소스미스클라인 바이오로지칼즈 에스.에이. 조성물
DK1869171T4 (en) * 2005-04-11 2016-01-18 Crucell Holland Bv Virus cleaning using ultrafiltration
ATE494906T1 (de) * 2005-11-01 2011-01-15 Novartis Vaccines & Diagnostic Von zellen stammende virale impfstoffe mit geringen mengen an rest-zell-dna
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
CN102755645A (zh) 2005-11-04 2012-10-31 诺华疫苗和诊断有限公司 佐剂配制的包含细胞因子诱导剂的流感疫苗
ES2377884T3 (es) 2005-11-04 2012-04-02 Novartis Vaccines And Diagnostics S.R.L. Vacunas contra la gripe que incluyen combinaciones de adyuvantes particulados e inmunopotenciadores
AU2006310163B2 (en) 2005-11-04 2011-09-15 Seqirus UK Limited Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
DE202006021242U1 (de) * 2005-11-04 2014-01-29 Novartis Vaccines And Diagnostics S.R.L. Emulsionen mit freiem wässrigen Phasen Tensid als Adjuvans für Spalt-Grippeimpfstoffe
JP2009514838A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル 細胞培養物において増殖されたインフルエンザウイルスから調製された非ビリオン抗原を含むアジュバントワクチン
DK2478916T3 (da) * 2006-01-27 2020-06-15 Seqirus Uk Ltd Influenzavacciner indeholdende hæmagglutinin og matrixproteiner
CA2646349A1 (en) 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Storage of influenza vaccines without refrigeration
WO2007126810A2 (en) 2006-03-31 2007-11-08 Warf - Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
WO2008009309A1 (en) 2006-07-17 2008-01-24 Glaxosmithkline Biologicals S.A. Influenza vaccine
GB0614460D0 (en) * 2006-07-20 2006-08-30 Novartis Ag Vaccines
ES2694805T7 (es) 2006-09-11 2021-10-21 Seqirus Uk Ltd Fabricación de vacunas contra virus de la gripe sin usar huevos
AU2007347716B2 (en) 2006-09-15 2013-06-20 Medimmune, Llc MDCK cell lines supporting viral growth to high titers and bioreactor process using the same
SG177141A1 (en) 2006-12-06 2012-01-30 Novartis Ag Vaccines including antigen from four strains of influenza virus
US8697154B2 (en) * 2007-03-05 2014-04-15 Om Pharma Sa Bacterial extract for respiratory disorders and process for its preparation
CA2680600A1 (en) 2007-03-12 2008-09-18 Antigen Express, Inc. Li-rnai involved li suppression in cancer immunotherapy
PE20090146A1 (es) 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
EP2185191B1 (en) 2007-06-27 2012-09-12 Novartis AG Low-additive influenza vaccines
AU2008293504B2 (en) * 2007-08-27 2012-04-12 Longhorn Vaccines & Diagnostics, Llc Immunogenic compositions and methods
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
CN101998990B (zh) 2008-03-18 2013-11-27 诺华股份有限公司 流感病毒疫苗抗原制备方法的改进
CN103952376A (zh) 2008-09-24 2014-07-30 米迪缪尼有限公司 培养细胞、增殖和纯化病毒的方法
EP2361304A2 (en) 2008-11-05 2011-08-31 GlaxoSmithKline Biologicals S.A. Novel method
JP5642712B2 (ja) 2009-02-10 2014-12-17 ノバルティス アーゲー 少ない量のスクアレンを含むインフルエンザワクチン
EA201171032A1 (ru) 2009-02-10 2012-02-28 Новартис Аг Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами
US20120093860A1 (en) 2009-02-10 2012-04-19 Novartis Ag Influenza vaccines with increased amounts of h3 antigen
USH2284H1 (en) 2009-04-27 2013-09-03 Novartis Ag Vaccines for protecting against influenza
KR101800245B1 (ko) 2009-05-21 2017-11-22 노파르티스 아게 비-내인성 pol i 프로모터를 사용하는 역 유전학
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
AU2010270722B2 (en) 2009-07-06 2015-06-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
WO2011012999A1 (en) 2009-07-31 2011-02-03 Novartis Ag Reverse genetics systems
KR20120081587A (ko) 2009-09-10 2012-07-19 노파르티스 아게 기도 질병에 대한 조합 백신
EP2491117B2 (en) 2009-10-20 2017-06-28 Novartis AG Improved reverse genetics methods for virus rescue
US9109013B2 (en) 2009-10-26 2015-08-18 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in vero cells
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
CA2800150C (en) 2010-05-21 2018-09-04 Novartis Ag Influenza virus reassortment method
CA2801151A1 (en) 2010-06-01 2011-12-08 Novartis Ag Concentration of vaccine antigens with lyophilization
KR20220163497A (ko) 2010-06-01 2022-12-09 노파르티스 아게 동결건조하지 않는 인플루엔자 백신 항원의 농축
EP2590674B1 (en) 2010-07-06 2017-02-22 Variation Biotechnologies Inc. Compositions and methods for treating influenza
US9517205B2 (en) 2010-08-20 2016-12-13 Seqirus UK Limited Soluble needle arrays for delivery of influenza vaccines
EP2663327A4 (en) 2011-01-13 2015-12-02 Variation Biotechnologies Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
AU2012205315B2 (en) 2011-01-13 2017-05-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
WO2013057715A1 (en) 2011-10-20 2013-04-25 Novartis Ag Adjuvanted influenza b virus vaccines for pediatric priming
EP2780350B1 (en) 2011-11-18 2019-03-06 Variation Biotechnologies Inc. Synthetic derivatives of mpl and uses thereof
CN104302323A (zh) 2012-01-12 2015-01-21 变异生物技术公司 用于治疗病毒感染的组合物和方法
AU2013213345A1 (en) 2012-01-27 2014-08-28 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents
JP6054883B2 (ja) 2012-03-02 2016-12-27 ノバルティス アーゲー インフルエンザウイルスの再集合
EP2855701A1 (en) 2012-06-04 2015-04-08 Novartis AG Improved safety testing
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
AU2013354219A1 (en) 2012-12-03 2015-07-02 Novartis Ag Reassortant influenza a viren
AU2014229255B2 (en) 2013-03-13 2018-12-13 Novartis Ag Influenza B virus reassortment
JP2016521282A (ja) 2013-05-10 2016-07-21 ノバルティス アーゲー インフルエンザワクチンにおけるナルコレプシーのリスクの回避
DE202013005130U1 (de) 2013-06-05 2013-09-10 Novartis Ag Influenza Virus Reassortierung
DE202013005100U1 (de) 2013-06-05 2013-08-26 Novartis Ag Influenza Virus Reassortierung
CA2914604A1 (en) 2013-06-06 2014-12-11 Novartis Ag Influenza virus reassortment
AU2014290203B2 (en) 2013-07-15 2020-12-24 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in MDCK or vero cells or eggs
RU2535153C1 (ru) * 2013-09-04 2014-12-10 Федеральное государственное унитарное предприятие "Санкт-Петербургский научно-исследовательский институт вакцин и сывороток и предприятие по производству бактерийных препаратов" Федерального медико-биологического агентства России (ФГУП СПбНИИВС ФМБА России) Способ получения высокоочищенных вирионных концентратов
JP6373376B2 (ja) 2013-11-15 2018-08-15 ノバルティス アーゲー 残留細胞培養不純物の除去
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
EP2966093A1 (en) 2014-07-07 2016-01-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Process for the preparation of magnetic sulfated cellulose particles, magnetic sulfated cellulose particles and their use
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
RU2614127C2 (ru) * 2015-06-04 2017-03-22 Общество с ограниченной ответственностью "НТфарма" Способ получения концентрата рекомбинантных псевдоаденовирусных частиц, экспрессирующих ген гемагглютинина вируса гриппа A/California/07/2009(H1N1)
KR20180035807A (ko) 2015-06-26 2018-04-06 세퀴러스 유케이 리미티드 항원적으로 매치된 인플루엔자 백신
WO2017007839A1 (en) 2015-07-06 2017-01-12 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
BR112018000296A2 (pt) 2015-07-07 2018-09-04 Seqirus UK Limited ensaios de potência de influenza
AU2017221444B2 (en) 2016-02-19 2021-07-29 Wisconsin Alumni Research Foundation (Warf) Improved influenza B virus replication for vaccine development
US11268071B2 (en) 2017-03-30 2022-03-08 Merck Sharp And Dohme Corp. Addition of nucleases directly to cell culture to facilitate digestion and clearance of host cell nucleic acids
RU2670001C1 (ru) * 2017-12-25 2018-10-17 Федеральное государственное бюджетное учреждение науки Институт биохимии и физиологии растений и микроорганизмов Российской академии наук Способ получения белков клеточной поверхности
WO2019139891A1 (en) 2018-01-09 2019-07-18 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
WO2019183209A1 (en) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
CA3094173A1 (en) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Intestinal alkaline phosphatase formulations
JP2022527235A (ja) 2019-01-23 2022-06-01 義裕 河岡 インフルエンザウイルスにおける付加的遺伝子に遺伝的安定性を付与する突然変異
CN113874496A (zh) 2019-02-08 2021-12-31 威斯康星校友研究基金会(Warf) 人源化细胞系
US11390649B2 (en) 2019-05-01 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
US11807872B2 (en) 2019-08-27 2023-11-07 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
JP2023502650A (ja) 2019-11-18 2023-01-25 セキラス ピーティーワイ リミテッド 遺伝子再集合インフルエンザウイルスを産生するための方法
KR102444684B1 (ko) * 2020-04-29 2022-09-16 에스케이바이오사이언스(주) 일회용 배양 공정 시스템을 이용한 인플루엔자 바이러스 생산 방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH589453A5 (xx) * 1974-01-14 1977-07-15 Sandoz Ag
US4500513A (en) * 1979-05-15 1985-02-19 Miles Laboratories, Inc. Influenza vaccine production in liquid cell culture
US4317811A (en) * 1980-09-11 1982-03-02 Merck & Co., Inc. Herpes simplex type 1 subunit vaccine
DE3237313A1 (de) * 1982-10-08 1984-04-12 Werner Heese Verfahren zur gewinnung und reinigung antigenhaltiger loesungen, insbesondere fuer influenza-viren, aus antigenhaltiger allantoisfluessigkeit
US4783411A (en) * 1984-10-22 1988-11-08 Janis Gabliks Influenza-A virus vaccine from fish cell cultures
US5173418A (en) * 1985-05-10 1992-12-22 Benzon Pharma, A/S Production in Escherichia coli of extracellular Serratia spp. hydrolases
US5006472A (en) * 1988-06-03 1991-04-09 Miles Inc. Enzymatic purification process
CA2026570C (en) * 1989-02-07 2000-05-30 Zeev Even-Chen Method for production and purification of hepatitis b vaccine
ATE132160T1 (de) * 1989-03-29 1996-01-15 Univ New York State Res Found Verfahren zur reinigung von aussenmembran-protein von haemophilus influenza
DZ1706A1 (fr) * 1992-08-07 2002-02-17 Merck & Co Inc Vaccin contre le virus de l'hepatite a.
HRP950097A2 (en) * 1994-03-08 1997-06-30 Merck & Co Inc Hepatitis a virus culture process
ES2378409T3 (es) * 1994-11-10 2012-04-12 Baxter Healthcare S.A. Método para producir sustancias biológicas en cultivo sin proteínas
US5681746A (en) * 1994-12-30 1997-10-28 Chiron Viagene, Inc. Retroviral delivery of full length factor VIII
KR19990036028A (ko) * 1995-08-01 1999-05-25 다니엘 케르니 일본뇌염 백신의 공업적인 생산방법 및 이에 의한 백신
CZ92998A3 (cs) * 1995-09-28 1998-09-16 University Of Pittsburgh Of The Commonwealth System Of Higher Education Způsob stimulace buněčně zprostředkované imunitní odpovědi pomocí cílené imunizace genovým materiálem vázaným na částicích

Also Published As

Publication number Publication date
DE69800383T2 (de) 2001-08-16
HRP980187A2 (en) 1999-04-30
NO323349B1 (no) 2007-04-02
JPH1121253A (ja) 1999-01-26
SK44598A3 (en) 1998-11-04
HU9800802D0 (en) 1998-05-28
SI0870508T1 (en) 2001-02-28
MX9802766A (es) 1998-12-31
JP5258127B2 (ja) 2013-08-07
KR100593235B1 (ko) 2007-12-04
CA2234208A1 (en) 1998-10-09
CN1196956A (zh) 1998-10-28
HK1010833A1 (en) 1999-07-02
HUP9800802A3 (en) 2003-08-28
PL187982B1 (pl) 2004-11-30
BR9801015A (pt) 2000-01-11
DE870508T1 (de) 1999-08-19
AR011216A1 (es) 2000-08-02
ES2129386T1 (es) 1999-06-16
DE69800383D1 (de) 2000-12-14
EP0870508B1 (en) 2000-11-08
AU728939B2 (en) 2001-01-18
EP0870508A1 (en) 1998-10-14
US5948410A (en) 1999-09-07
NO981557L (no) 1998-10-12
ZA982915B (en) 1999-01-21
PT870508E (pt) 2001-04-30
NZ330131A (en) 1999-10-28
HUP9800802A2 (hu) 1999-04-28
UA42089C2 (uk) 2001-10-15
NO981557D0 (no) 1998-04-06
DZ2462A1 (fr) 2003-01-18
RU2197264C2 (ru) 2003-01-27
TW570803B (en) 2004-01-11
TR199800613A1 (xx) 1998-10-21
ID20399A (id) 1998-12-10
CZ105098A3 (cs) 1998-10-14
CN1138564C (zh) 2004-02-18
ATE197406T1 (de) 2000-11-11
CZ297492B6 (cs) 2007-01-03
IL123961A (en) 2000-07-16
DK0870508T3 (da) 2000-11-20
GR3034798T3 (en) 2001-02-28
ES2129386T3 (es) 2001-01-01
SK282614B6 (sk) 2002-10-08
AU6065998A (en) 1998-10-15
GR990300017T1 (en) 1999-06-30
CA2234208C (en) 2003-06-10
KR19980081114A (ko) 1998-11-25
PL325722A1 (en) 1998-10-12

Similar Documents

Publication Publication Date Title
GR3034798T3 (en) Influenza vaccine
GB9712347D0 (en) Vaccine
GB9718901D0 (en) Vaccine
IL136446A0 (en) Vaccine
GB9711990D0 (en) Vaccine
GB9726555D0 (en) Vaccine
GB9720585D0 (en) Vaccine
AU1308495A (en) Influenza vaccine
EP1083926A4 (en) VACCINE
IL132121A0 (en) Leishmania vaccine
GB0027072D0 (en) Vaccine
ZA982763B (en) Vaccines
GB9702990D0 (en) Virus vaccine
GB9718616D0 (en) Oral vaccine
GB9720982D0 (en) Vaccine
GB9718902D0 (en) Vaccine
GB9717423D0 (en) Vaccine
GB9725241D0 (en) Hiv vaccine
GB9703202D0 (en) HIV vaccine
GB9702920D0 (en) Vaccines
GB9701200D0 (en) Targeted allergy vaccine
GB9802650D0 (en) Vaccine
GB9805960D0 (en) Vaccine
GB9811954D0 (en) Vaccine
GB9805958D0 (en) Vaccine

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
PPPP Transfer of rights

Owner name: SOLVAY BIOLOGICALS B.V., NL

PNAN Change of the applicant name, address/residence

Owner name: ABBOTT BIOLOGICALS B.V., NL

PPPP Transfer of rights

Owner name: BGP PRODUCTS B.V., NL

ODRP Renewal fee for the maintenance of a patent

Payment date: 20170404

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20180406